Skip to main content
UCB logo

UCB — Investor Relations & Filings

Ticker · UCB ISIN · BE0003739530 LEI · 2138008J191VLSGY5A09 BR Manufacturing
Open in API
Filings indexed 2,023 across all filing types
Latest filing 2013-09-20 Capital/Financing Update
Country BE Belgium
Listing BR UCB

About UCB

https://www.ucb.com/

UCB is a global biopharmaceutical company that focuses on creating solutions for people living with severe diseases, primarily in the fields of neurology and immunology. The company's core activities include the research, development, and commercialization of pharmaceutical and biotechnology products. Guided by a patient-centric and science-driven approach, UCB is committed to innovation and sustainability. Through its UCB Ventures arm, it invests in pioneering technologies and companies with the potential to transform patient care. The company also offers personalized support services to patients and healthcare professionals during their treatment journey with a UCB medicine.

Recent filings

Filing Released Lang Actions
Resultaten van het openbaar aanbod tot omruiling van de obligaties met vervaldatum in november 2014
Capital/Financing Update Classification · 99% confidence The document is a press release dated September 20, 2013, detailing the results of a tender offer (Ruilbod) for existing bonds maturing in November 2014, resulting in the issuance of new bonds maturing in 2023. This announcement concerns a specific financing activity—the exchange and restructuring of debt instruments. This aligns directly with the definition of 'Capital/Financing Update' (CAP), which covers company fundraising, financing activities, or capital structure changes. It is not a full annual report (10-K), an earnings release (ER), or a general regulatory filing (RNS), as it pertains to a specific capital transaction.
2013-09-20 Dutch
UCB receives CHMP positive opinion for Cimzia® in severe active axial spondyloarthritis
Regulatory Filings Classification · 95% confidence The document is a press release from UCB dated September 20, 2013, announcing that the CHMP (Committee for Medicinal Products for Human Use) adopted a positive opinion recommending the extension of marketing authorization for Cimzia® for severe active axial spondyloarthritis (axSpA). This content focuses on a regulatory/clinical development milestone (positive opinion from EMA's CHMP) related to a drug application, rather than a full financial report (10-K, IR), a management change (MANG), or a general shareholder meeting material (AGM-R, DEF 14A). It is a specific announcement regarding a regulatory/clinical outcome. While it contains clinical trial data, its primary purpose is to communicate a regulatory step forward. This fits best under the general category of Regulatory Filings (RNS) as a specific regulatory update that isn't a formal financial report or a specific management/governance filing. It is not an Earnings Release (ER) as it does not contain period financial results.
2013-09-20 English
UCB reçoit l’avis positif du CHMP pour l’emploi de Cimzia® dans le traitement de la spondylarthrite axiale active sévère
Regulatory Filings Classification · 95% confidence The document is a press release from UCB announcing that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for the use of Cimzia® (certolizumab pegol) in treating severe active axial spondyloarthritis (axSpA). This announcement details clinical trial data (RAPID™-axSpA study), regulatory steps (CHMP opinion, expected European Commission decision), and provides extensive safety information for the drug. This content structure—a formal announcement of a regulatory milestone related to a drug's approval/indication extension, including clinical evidence and safety warnings—is characteristic of a press release accompanying a major regulatory or clinical development, rather than a comprehensive annual report (10-K), a quarterly report (IR), or a general regulatory filing (RNS). Since it is a specific announcement about a drug approval/indication, and there is no specific code for 'Drug Regulatory Update', the closest fit among the provided options that captures a significant, non-financial, specific corporate announcement is often categorized under general regulatory or informational releases. However, given the focus on clinical trial results and regulatory opinions, it is a specific corporate communication. It is not an Earnings Release (ER), a Call Transcript (CT), or a standard Investor Presentation (IP). It is a specific corporate announcement regarding a regulatory decision. Since it is not a standard financial report, and it is not a proxy statement, director dealing, or dividend notice, it falls best under the general 'Regulatory Filings' (RNS) category as a fallback for specific, non-financial regulatory news, or potentially an 'LTR' if viewed as a major product development announcement, but RNS is the most appropriate general regulatory announcement category when a more specific one is missing. Given the context of a press release detailing a positive CHMP opinion, it is a significant regulatory announcement, best classified as RNS (Regulatory Filings) as the catch-all for such specific, non-financial regulatory news.
2013-09-20 French
UCB krijgt positieve beoordeling van CHMP voor Cimzia® bij ernstige actieve axiale spondyloartritis
Regulatory Filings Classification · 95% confidence The document is a press release from UCB dated September 20, 2013, announcing a positive opinion from the CHMP (Committee for Medicinal Products for Human Use) of the EMA regarding the extension of marketing authorization for Cimzia® for severe active axial spondyloarthritis (axSpA). It details clinical trial data (RAPID™-axSpA study), safety information, and expected regulatory timelines (European Commission decision expected in Q4 2013). This content is characteristic of an official company announcement regarding regulatory progress or clinical trial results, but it is not a formal regulatory filing like a 10-K, nor is it a transcript or a formal earnings release. Since it is a specific announcement about a drug approval process and includes detailed medical/regulatory context, it fits best under the general category of Regulatory Filings (RNS) as a press release detailing regulatory milestones, or potentially an Investor Presentation (IP) if it were structured as such, but given the format, RNS is the most appropriate general regulatory announcement category when specific categories like ER or CT don't apply. However, looking closely at the definitions, this is a company announcement about a regulatory event, which often falls under RNS (Regulatory Filings - general fallback) or sometimes ER if it were tied to earnings, but here it is purely regulatory/product news. Since it is a news release announcing a regulatory opinion, RNS is the best fit among the provided options for a non-standard, non-financial core report announcement.
2013-09-20 Dutch
Acquisition of own shares_ENG (18-09).pdf
Transaction in Own Shares Classification · 99% confidence The document is explicitly titled "Acquisition of own shares" and details a transaction where UCB SA/NV acquired 150,000 UCB shares OTC following the exercise of an early termination right under a share swap. This action directly relates to the company buying back or repurchasing its own shares. This aligns perfectly with the definition for Transaction in Own Shares (POS). The document is a formal announcement of this specific corporate action, not a general regulatory filing (RNS) or a report announcement (RPA).
2013-09-18 English
Acquisition of own shares_FR (18-09).pdf
Transaction in Own Shares Classification · 99% confidence The document is titled "Acquisition d'actions propres" (Acquisition of own shares) and details a transaction where UCB SA sold 150,000 of its own shares following the settlement of a share swap agreement. It explicitly states the number of shares held after the transaction and references the relevant Belgian Royal Decree article concerning the acquisition of own shares. This activity directly corresponds to the definition of a company buying back or selling its own shares, which maps to the 'Transaction in Own Shares' category (POS). The document is a formal announcement of this specific corporate action, not a general regulatory filing (RNS) or a report itself.
2013-09-18 French

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.